Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
IL3-H52G3 | Human | Human IL-13 Protein, GST Tag |
|
||
IL3-C5249 | Cynomolgus | Cynomolgus IL-13 Protein, His Tag (MALS verified) |
|
||
IL3-M5249 | Mouse | Mouse IL-13 Protein, His Tag |
|
||
IL3-C52H4 | Canine | Canine IL-13 Protein, His Tag |
|
||
IL3-H82E5 | Human | Biotinylated Human IL-13 Protein, His,Avitag™ (MALS verified) |
|
||
IL3-H5256 | Human | Human IL-13 Protein, Fc Tag |
|
||
IL3-H52H4 | Human | Human IL-13 Protein, His Tag |
|
Biotinylated Human IL-13 R alpha 1 Protein, His,Avitag (Cat. No. IL1-H82E8) captured on Biotin CAP-Series S Sensor Chip can bind Human IL-13 Protein, His Tag (Cat. No. IL3-H52H4) with an affinity constant of 34.4 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Berdazimer sodium-SB-206 (Novan) | NVN-1000-SB-206-Novan; MAP3-NONOate - SB-206; NVN1000-SB206; SB-206; SB-019; NI-MC101 | Approved | Zelsuvmi, ZELSUVMI, KINSOLUSTM | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Tinea Pedis; Psoriasis; Molluscum Contagiosum; Condylomata Acuminata; Dermatitis, Atopic | Details | |
Lebrikizumab | RO-4909832; PRO-301444; DRM-06; Anti-IL-13; TNX-650; RG-3637; RO-5490255; MILR-1444A; R-3637; DRM 06; LY 3650150; MILR1444A; MILR1444Ab; RG 3637; RO 5490255; TNX 650 | Approved | Tanox Inc | EBGLYSS | EU | Dermatitis, Atopic | Almirall Sa | 2023-11-16 | Idiopathic Pulmonary Fibrosis; Hodgkin Disease; Skin Diseases; Dermatitis; Asthma; Sinusitis; Alzheimer Disease; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Eczema; Skin Diseases, Genetic | Details |
Tralokinumab | BAK-502G9; CAT-354 | Approved | Medimmune Llc | Adtralza, ADBRY | EU | Dermatitis, Atopic | Leo Pharma A/S | 2021-06-17 | Idiopathic Pulmonary Fibrosis; Colitis, Ulcerative; Asthma; Dermatitis, Atopic; Eczema | Details |
Berdazimer sodium-SB-206 (Novan) | NVN-1000-SB-206-Novan; MAP3-NONOate - SB-206; NVN1000-SB206; SB-206; SB-019; NI-MC101 | Approved | Zelsuvmi, ZELSUVMI, KINSOLUSTM | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Tinea Pedis; Psoriasis; Molluscum Contagiosum; Condylomata Acuminata; Dermatitis, Atopic | Details | |
Lebrikizumab | RO-4909832; PRO-301444; DRM-06; Anti-IL-13; TNX-650; RG-3637; RO-5490255; MILR-1444A; R-3637; DRM 06; LY 3650150; MILR1444A; MILR1444Ab; RG 3637; RO 5490255; TNX 650 | Approved | Tanox Inc | EBGLYSS | EU | Dermatitis, Atopic | Almirall Sa | 2023-11-16 | Idiopathic Pulmonary Fibrosis; Hodgkin Disease; Skin Diseases; Dermatitis; Asthma; Sinusitis; Alzheimer Disease; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Eczema; Skin Diseases, Genetic | Details |
Tralokinumab | BAK-502G9; CAT-354 | Approved | Medimmune Llc | Adtralza, ADBRY | EU | Dermatitis, Atopic | Leo Pharma A/S | 2021-06-17 | Idiopathic Pulmonary Fibrosis; Colitis, Ulcerative; Asthma; Dermatitis, Atopic; Eczema | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Berdazimer sodium-SB-204 (Novan) | MAP3-NONOate-SB-204; NVN1000-SB204; SB-204 | Phase 3 Clinical | University Of North Carolina At Chapel Hill | Acne Vulgaris | Details |
Cendakimab | RPC-4046; ABT-308; CC-93538 | Phase 3 Clinical | Abbott Laboratories | Eosinophilic gastroenteritis (EG); Eosinophilic Esophagitis; Asthma; Dermatitis, Atopic; Eczema | Details |
Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Lymphedema; Asthma | Details |
PF-07264660 | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Asthma; Inflammation | Details |
APG-777 | APG777; APG-777; PR004; PR-004 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Dermatitis, Atopic | Details |
SAR-443726 | SAR-443726 | Phase 1 Clinical | Sanofi | Dermatitis, Atopic | Details |
BD-9 | BD-9 | Biolojic Design Inc | Details | ||
Berdazimer sodium-SB-204 (Novan) | MAP3-NONOate-SB-204; NVN1000-SB204; SB-204 | Phase 3 Clinical | University Of North Carolina At Chapel Hill | Acne Vulgaris | Details |
Cendakimab | RPC-4046; ABT-308; CC-93538 | Phase 3 Clinical | Abbott Laboratories | Eosinophilic gastroenteritis (EG); Eosinophilic Esophagitis; Asthma; Dermatitis, Atopic; Eczema | Details |
Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Lymphedema; Asthma | Details |
PF-07264660 | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Asthma; Inflammation | Details |
APG-777 | APG777; APG-777; PR004; PR-004 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Dermatitis, Atopic | Details |
SAR-443726 | SAR-443726 | Phase 1 Clinical | Sanofi | Dermatitis, Atopic | Details |
BD-9 | BD-9 | Biolojic Design Inc | Details |
This web search service is supported by Google Inc.